BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 38686358)

  • 1. The Role of Direct Oral Anticoagulants in the Treatment of Cancer-Associated Venous Thromboembolism: Review by Middle East and North African Experts.
    Bazarbashi S; El Zawahry HM; Owaidah T; AlBader MA; Warsi A; Marashi M; Dawoud E; Jaafar H; Sholkamy SM; Haddad F; Cohen AT
    J Blood Med; 2024; 15():171-189. PubMed ID: 38686358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants.
    Ay C; Beyer-Westendorf J; Pabinger I
    Ann Oncol; 2019 Jun; 30(6):897-907. PubMed ID: 30918939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats.
    O'Connell C; Escalante CP; Goldhaber SZ; McBane R; Connors JM; Raskob GE
    Oncologist; 2021 Jan; 26(1):e8-e16. PubMed ID: 33275319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct Oral Anticoagulants for the Treatment of Cancer-Associated Venous Thromboembolism: A Latin American Perspective.
    Athanazio RA; Ceresetto JM; Marfil Rivera LJ; Cesarman-Maus G; Galvez K; Marques MA; Tabares AH; Ortiz Santacruz CA; Santini FC; Corrales L; Cohen AT
    Clin Appl Thromb Hemost; 2022; 28():10760296221082988. PubMed ID: 35261295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
    Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safe and effective treatment of venous Thromboembolism associated with Cancer: focus on direct Oral Anticoagulants in Asian patients.
    Lee LH; Danchaivijitr P; Uaprasert N; Gill H; Sacdalan DL; Ho GF; Parakh R; Pai P; Lee JK; Rey N; Cohen AT
    Exp Hematol Oncol; 2022 Oct; 11(1):79. PubMed ID: 36303259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of venous thromboembolism in patients with cancer: from clinical trials to real life.
    Verso M; Agnelli G
    Thromb Res; 2020 Jul; 191 Suppl 1():S123-S127. PubMed ID: 32736770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Direct Oral Anticoagulants in Venous Thromboembolism Compared to Traditional Anticoagulants in Morbidly Obese Patients: A Systematic Review and Meta-Analysis.
    Katel A; Aryal M; Neupane A; Gosain R; Pathak R; Bhandari Y; Kouides P
    Cureus; 2021 Apr; 13(4):e14572. PubMed ID: 34026385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct Oral Anticoagulants in Patients With Active Cancer: A Systematic Review and Meta-Analysis.
    Sabatino J; De Rosa S; Polimeni A; Sorrentino S; Indolfi C
    JACC CardioOncol; 2020 Sep; 2(3):428-440. PubMed ID: 34396250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism: A systematic review and Bayesian network meta-analysis.
    Ning H; Yang N; Ding Y; Chen H; Wang L; Han Y; Cheng G; Zou M
    Med Clin (Barc); 2023 Mar; 160(6):245-252. PubMed ID: 36031454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct oral anticoagulants for venous thromboembolism in cancer patients: a systematic review and network meta-analysis.
    Wu S; Lv M; Chen J; Jiang S; Chen M; Fang Z; Zeng Z; Qian J; Xu W; Guan C; Zhang J
    Support Care Cancer; 2022 Dec; 30(12):10407-10420. PubMed ID: 36318341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: A systematic review and meta-analysis.
    Alhousani M; Malik SU; Abu-Hashyeh A; Poznanski NJ; Al-Hasan S; Roth DF; Alsharedi M; Mustafa B
    Thromb Res; 2021 Feb; 198():103-114. PubMed ID: 33310644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of direct oral anticoagulants versus low molecular weight heparins for venous thromboembolism treatment in patients with gastrointestinal malignancies.
    Guan T; Laguna A; Soares A; Legasto CS; Block S; Saunders IM; Alvarez K; Pon T; Patel N; Mahajan A; Lee A
    J Thromb Thrombolysis; 2023 Oct; 56(3):439-446. PubMed ID: 37421494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism.
    Recio-Boiles A; Veeravelli S; Vondrak J; Babiker HM; Scott AJ; Shroff RT; Patel H; Elquza E; McBride A
    World J Gastrointest Oncol; 2019 Oct; 11(10):866-876. PubMed ID: 31662825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism.
    Voigtlaender M; Langer F
    Hamostaseologie; 2017; 37(4):241-255. PubMed ID: 29582927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants.
    Vedovati MC; Giustozzi M; Becattini C
    Thromb Res; 2019 May; 177():33-41. PubMed ID: 30849513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct oral anticoagulant versus low-molecular-weight heparin for treatment of venous thromboembolism in cancer patients: An updated meta-analysis of randomized controlled trials.
    Haykal T; Zayed Y; Deliwala S; Kerbage J; Ponnapalli A; Malladi S; Goranta S; Samji V; Adam S
    Thromb Res; 2020 Oct; 194():57-65. PubMed ID: 32788122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of Direct Oral Anticoagulants in Central Nervous System Malignancies.
    Swartz AW; Drappatz J
    Oncologist; 2021 May; 26(5):427-432. PubMed ID: 33523555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient).
    Pernod G; Joly M; Sonnet B
    J Med Vasc; 2020 Nov; 45(6S):6S17-6S23. PubMed ID: 33276939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Direct Oral Anticoagulants for Secondary Prevention of Cancer-Associated Thrombosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies.
    Wang Y; Lv H; Li D; Chen C; Gu G; Sun Y; Yang X; Liu Y; Fang F; Liu J; Tse G; Xia Y
    Front Pharmacol; 2019; 10():773. PubMed ID: 31354488
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.